

## Media release

### Janne Mäki-Kahra to head Straumann OY, Finland

**Basel, 6 June 2005:** Straumann, the world's second largest manufacturer of dental implants and oral tissue regeneration products today announced the appointment of Mr Janne Mäki-Kahra as Head of Straumann OY, Finland. Mr Mäki-Kahra is a seasoned professional with a strong track record in sales, project leadership, brand management and key account management. He joins Straumann from Aventis Pharma in Finland having previously worked for Novartis, Biomet Merck, and Stryker. A large part of his career has been spent in the fields of bone and cardiovascular treatments as well as spinal and neurosurgical products. Janne Mäki-Kahra graduated as a physiotherapist and holds a diploma in business and management.

Mr Mäki-Kahra takes over from Kristiina Lehtikoinen, who is pursuing further education outside our industry. During the past two decades, Mrs Lehtikoinen has played a considerable role in establishing Straumann as the clear market leader in Finland. She will continue as a member of the Board of Straumann Finland.

#### About Straumann

Headquartered in Basel, Switzerland, Straumann (SWX: STMN) is a global leader in implant dentistry and dental tissue regeneration. In collaboration with the International Team for Implantology (ITI), leading clinics, research institutes and universities, the Group researches, develops, produces and distributes implants, instruments and tissue regeneration products for use in tooth replacement solutions or to prevent tooth loss. Straumann also provides training and services to the dental profession worldwide. The Group's implants and instruments are manufactured in Switzerland, whilst its dental tissue regeneration products are produced in Sweden. Straumann's products and services are available in more than 60 countries worldwide through the Group's 15 distribution subsidiaries and a broad network of distribution partners. Straumann employs 1177 people worldwide, and generated sales of CHF 420 million and a net income of CHF 101 million in 2004.

#### Contact:

Corporate Communication  
+41 (0)61 965 11 11  
[corporate.communication@straumann.com](mailto:corporate.communication@straumann.com)

---

#### Disclaimer

This press release contains certain "forward-looking statements" which reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group's products, the potential for the Group's products to become obsolete, the Group's ability to defend its intellectual property, the Group's ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group's ability to generate revenues and profitability, and the Group's ability to realize its collaboration projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

**Institut Straumann AG**, Peter Merian-Weg 12, 4002 Basel, Switzerland.  
Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01  
Homepage: [www.straumann.com](http://www.straumann.com)